Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Germany says AstraZeneca lawsuit "not priority" for now

Fri, 23rd Apr 2021 12:53

(Alliance News) - Germany would support legal action against AstraZeneca PLC for under-delivering Covid-19 vaccine doses to the EU, but the priority now should be on securing the jabs, Health Minister Jens Spahn said Friday.

The European Commission is considering a lawsuit against the Swedish-British pharmaceutical giant for so far delivering just 31 million of the 120 million doses it had promised, according to EU diplomats.

Asked if he thought the lawsuit was a good idea, Spahn said: "If (the commission) decides to take legal action, then yes... but it's much more important to me that I get this vaccine."

Germany wants to "cooperate with AstraZeneca to get as many deliveries as possible as quickly as possible", he said, adding that legal issues are "not yet a priority in this phase of the pandemic".

EU diplomats said Thursday no final decision has been taken on legal action but the EU executive has informed member state envoys and wants them to confirm whether they would back a lawsuit.

"As you know, AstraZeneca is not delivering the number of doses which have been agreed upon in the contract... This is one of the reasons why we keep our options open together with member states to take any further steps," commission spokesman Stefan De Keersmaecker said on Thursday.

One diplomat told AFP that "not all member states are in agreement" on taking the company to court, stressing that their aim was simply to have AstraZeneca deliver the doses it had promised in its contract.

Public confidence in the AstraZeneca jab has taken a blow after the European Medicines Agency, the bloc's regulator, said it was likely linked to a very rare form of blood clot affecting the brain. 

The EMA and the commission have not changed their stance on a general use of AstraZeneca, saying its benefits outweigh the risks, but several EU countries have restricted its use to older citizens.

The EU, however, is now increasingly relying on the BioNTech SE/Pfizer Inc vaccine for its rollout, which has been accelerating since the end of March.

source: AFP

Copyright 2021 Alliance News Limited. All Rights Reserved.

Related Shares

More News
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslode...

18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with infla...

18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with pacl...

17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "impo...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.